开源证券股份有限公司、国联民生证券承销保荐有限公司 关于山东中创软件商用中间件股份有限公司 首次公开发行部分限售股上市流通的核查意见 本次上市流通的限售股均为公司首次公开发行战略配售限售股。根据《山东中 创软件商用中间件股份有限公司首次公开发行股票科创板上市公告书》，深圳开源、 民生投资承诺获得本次配售的股票持有期限为自公司首次公开发行并上市之日起 24个月。限售期届满后，深圳开源、民生投资对获配股份的减持适用中国证券监督 管理委员会和上海证券交易所关于股份减持的有关规定。 除上述承诺外，本次申请上市流通的限售股股东无其他特别承诺。 截至本公告披露日，本次申请解除股份限售的股东在限售期内均严格履行了上 述承诺，不存在未履行相关承诺而影响本次限售股上市流通的情况。 开源证券股份有限公司、国联民生证券承销保荐有限公司作为山东中创软件 商用中间件股份有限公司（以下简称"公司"）首次公开股票并在科创板上市的 保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股 票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等 相关规定，对公司首次公开发行部分限售股上市流通的事项进行了核查， ...

证券代码：688695 证券简称：中创股份 公告编号：2026-006 本次股票上市流通日期为2026 年 3 月 13 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于2023年5月11日印发的《关于同意山东中创软件 商用中间件股份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1066 号）的决定，山东中创软件商用中间件股份有限公司获准向社会公开发行人民币普 通股（A股）21,262,845股，并于2024年3月13日在上海证券交易所科创板上市，首次 公开发行股票后总股本为85,051,378股，其中有限售条件流通股67,066,313股，占 公司总股本的78.85%，无限售条件流通股17,985,065股，占公司总股本的21.15%。 山东中创软件商用中间件股份有限公司 首次公开发行战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式 为网下，上市股数为2,126,284股。本公司确认 ...

智通财经APP讯，中创股份(688695.SH)披露2025年度业绩快报，2025年度公司实现营业收入1.57亿元， 同比下降18.99%;归属于母公司所有者的净利润亏损2028.58万元，同比由盈转亏。 报告期内，受市场波动、行业竞争加剧等因素综合影响，公司营业收入较同期有所下降。报告期内，公 司根据客户及市场需求变化，持续加大研发投入力度，着力提升产品竞争力，导致本期研发费用上升; 与此同时，公司为进一步拓展市场份额、强化市场布局，对销售团队进行扩充优化，销售费用较去年同 期有所增加;此外，信用减值损失计提金额相比同期有所增加。上述因素对本期利润产生一定影响。 ...

Group 1 - Hehe Information achieved operating revenue of 1.81 billion yuan in 2025, a year-on-year increase of 25.83%, and net profit of 454 million yuan, a year-on-year increase of 13.39% [1] - Shengyi Technology announced that Guangxin Group and Chen Renxi have completed their share reduction plan, with Guangxin Group reducing its shares by 24.29 million, accounting for 1% of the total share capital [2] - Huaci Co., Ltd. received approval from the China Securities Regulatory Commission for its stock issuance to specific targets [3] Group 2 - New Nuo Wei plans to transfer 30.07% of its shares in Guoxin Huijin to Shiyao Holdings for 230 million yuan, with a valuation increase of 94.85% [4] - Tianli Lithium Energy has completed the scheduled maintenance of its lithium iron phosphate production line and resumed production [5] - Jinchuan Electric reported a net profit of 81.218 million yuan in 2025, a year-on-year decrease of 10.87% [6] Group 3 - Shenzhou Taiyue reported a net profit of 798 million yuan in 2025, a year-on-year decrease of 44.09% [7] - Jingwei Hengrun achieved a net profit of 99.5375 million yuan in 2025, reversing a loss from the previous year [8] - Keheng Technology signed a maximum pledge contract worth 450 million yuan to support its supply chain procurement [9] Group 4 - Zhongchu Media reported a net loss of 20.2858 million yuan in 2025, with operating revenue of 157 million yuan, a year-on-year decrease of 18.99% [10] - Tongde Chemical's subsidiary is involved in a lawsuit with a claim amount of approximately 49.1824 million yuan [12] - Jichuan Pharmaceutical signed an exclusive commercialization rights agreement for a new eczema treatment, with payments not exceeding 190 million yuan [13] Group 5 - Tianli Lithium Energy reported a net loss of 211 million yuan in 2025, with operating revenue of 408 million yuan, a year-on-year decrease of 20.20% [14] - Fortune Trend achieved a net profit of 315 million yuan in 2025, a year-on-year increase of 3.62% [15] - CITIC Securities received approval to publicly issue corporate bonds totaling no more than 80 billion yuan [16] Group 6 - Yongshan Lithium Industry reported a reduction of 23 million shares by Ningbo Jutai, decreasing its total shareholding from 13.24% to 4.52% [17] - Taifu Pump Industry achieved a net profit of 17.5631 million yuan in 2025, a year-on-year increase of 38.78% [18] - Longxun Co., Ltd. reported a net profit of 172 million yuan in 2025, a year-on-year increase of 19.05% [19] Group 7 - Duori Pharmaceutical's acquisition offer period has expired, and the company's stock will resume trading [20] - Tianhao Energy obtained a loan commitment letter for stock repurchase from a financial institution, with a loan amount not exceeding 90 million yuan [21] - Lijun Co., Ltd. reported a net profit of 57.545 million yuan in 2025, a year-on-year decrease of 52.09% [22] Group 8 - Zhongchumai reported a net profit of 212 million yuan in 2025, a year-on-year increase of 45.55% [23] - Kangxino reported a net profit of 27.8727 million yuan in 2025, reversing a loss from the previous year [24] - Baiao Saitu achieved a net profit of 173 million yuan in 2025, a year-on-year increase of 416.37% [25] Group 9 - Guangxun Technology's private placement application was approved by the Shenzhen Stock Exchange [26] - Sandam Membrane reported a net profit of 378 million yuan in 2025, a year-on-year increase of 19.95% [27] - Shangsheng Electronics reported a net profit of 184 million yuan in 2025, a year-on-year decrease of 21.71% [28] Group 10 - Xin'an Century reported a net profit of 79.2904 million yuan in 2025, reversing a loss from the previous year [29] - Zhenlei Technology achieved a net profit of 133 million yuan in 2025, a year-on-year increase of 582.01% [30] - Fuan Pharmaceutical's subsidiary received approval for a new drug application [32] Group 11 - Baotai reported a net loss of 336 million yuan in 2025, with operating revenue of 934 million yuan [33] - Aohua Endoscope reported a net profit of 11.4619 million yuan in 2025, a year-on-year decrease of 45.45% [34] - Maide Medical reported a net profit of 65.2599 million yuan in 2025, reversing a loss from the previous year [35] Group 12 - Chip Original Co. reported a net loss of 528 million yuan in 2025, with operating revenue of 3.152 billion yuan [36] - Zhongwei Semiconductor set a preliminary transfer price of 43.35 yuan per share for its inquiry [37] - Tieke Railway reported a net profit of 171 million yuan in 2025, a year-on-year decrease of 20.09% [38] Group 13 - Changjiang Electric announced a cash dividend distribution plan of 2.1 yuan per 10 shares for the 2025 fiscal year [39] - Kunheng Shunwei reported a net profit of 46.7676 million yuan in 2025, a year-on-year increase of 26.28% [40] - Ailis reported a net profit of 2.181 billion yuan in 2025, a year-on-year increase of 52.55% [41] Group 14 - Aerospace Software reported a net loss of 11.3126 million yuan in 2025, with operating revenue of 1.216 billion yuan [42] - Qizhong Technology reported a net profit of 266 million yuan in 2025, a year-on-year decrease of 15.16% [43] - Guotou Zhonglu plans to acquire 70% of Luochuan Lingxian Company for 74.8745 million yuan [44] Group 15 - Aokema plans to acquire 45% of its subsidiary for 253 million yuan [45] - ST Dali signed a procurement framework agreement worth 88.8794 million yuan with a leading new energy company [46] - Zhifei Biological received clinical trial approval for a new mRNA vaccine [47]

格隆汇2月26日丨中创股份(688695.SH)公布2025年度业绩快报，本报告期，公司实现营业收入15,736.17 万元，较上年同期下降18.99%；实现归属于母公司所有者的净利润-2,028.58万元，同比下降152.40%； 实现归属于母公司所有者的扣除非经常性损益的净利润-2,811.14万元，同比下降178.54%。 报告期内，公司根据客户及市场需求变化，持续加大研发投入力度，着力提升产品竞争力，导致本期研 发费用上升；与此同时，公司为进一步拓展市场份额、强化市场布局，对销售团队进行扩充优化，销售 费用较去年同期有所增加；此外，信用减值损失计提金额相比同期有所增加。上述因素对本期利润产生 一定影响。 ...

证券代码：688695 证券简称：中创股份 公告编号：2026-005 本公告所载山东中创软件商用中间件股份有限公司（以下简称"公司"） 2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以 公司2025年年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 山东中创软件商用中间件股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业总收入 | 15,736.17 | 19,425.37 | | -18.99 | | 营业利润 | -2,536.04 | 4,099.95 | | -161.86 | | 利润总额 | -2,550.56 | 4,097.90 | | -162.24 | | 归属于母公司所有者 | -2,028.58 | 3,871. ...

Group 1 - The core transaction involved Zhongchuang Co., with a total of 500,000 shares traded, amounting to 11.39 million yuan, which represented 31.54% of the total trading volume for the day [1] - The transaction price was set at 22.78 yuan per share, reflecting a discount of 20.88% compared to the market closing price of 28.79 yuan [1] - The buying brokerage for this transaction was identified as "Company Zhengyi Energy" [2]

Core Viewpoint - Zhongchuang Co., Ltd. (688695.SH) is expected to report a significant loss in net profit attributable to shareholders for the year 2025, with an estimated loss of approximately 24 million yuan, representing a year-on-year decrease of about 161.99% [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is around -24 million yuan, a decrease of approximately 62.72 million yuan compared to the previous year [1] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around -31.55 million yuan, reflecting a year-on-year decrease of about 188.14% [1] Reasons for Performance Change - The decline in net profit is primarily attributed to market fluctuations and intensified industry competition, leading to a year-on-year decrease in operating revenue [1] - The company has increased its investment in research and development as well as market expansion, resulting in higher research and sales expenses compared to the previous year [1] - Additionally, the company has made provisions for credit impairment losses on accounts receivable in accordance with relevant regulations [1]

Core Viewpoint - Zhongchuang Co., Ltd. (688695.SH) is expected to report a significant loss in net profit attributable to shareholders for the year 2025, with an estimated loss of approximately 24 million yuan, representing a year-on-year decrease of about 161.99% [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is around -24 million yuan, a decrease of approximately 62.72 million yuan compared to the previous year [1] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around -31.55 million yuan, reflecting a year-on-year decrease of about 188.14% [1] Reasons for Performance Change - The decline in net profit is primarily attributed to market fluctuations and intensified industry competition, leading to a year-on-year decrease in operating revenue [1] - The company has increased its investment in research and development as well as market expansion, resulting in higher research and sales expenses compared to the previous year [1] - Additionally, the company has made provisions for credit impairment losses on accounts receivable in accordance with relevant regulations [1]

Financial Performance - The company expects a net loss attributable to shareholders of approximately -24 million CNY for 2025, a decrease of about 62.72% compared to the previous year[3] - The net profit excluding non-recurring gains and losses is projected to be around -31.55 million CNY, representing a year-on-year decrease of approximately 188.14%[3] - The previous year's net profit attributable to shareholders was 38.72 million CNY, with a total profit of 40.98 million CNY[5] - The company reported earnings per share of 0.49 CNY in the previous year[6] Factors Affecting Performance - The decline in net profit is primarily due to market fluctuations and intensified industry competition, leading to a decrease in operating revenue[7] - The company has increased its R&D and marketing expenses, contributing to the projected losses[7] - The company has made provisions for credit impairment losses on accounts receivable as per relevant regulations[7] Forecast and Risks - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by certified public accountants[4] - Investors are advised to pay attention to investment risks as the forecast data is subject to change pending the audited annual report[9] - The announcement was made by the company's board on January 30, 2026[11]